DP VIII Associates, L.P. 4
4 · BioNano Genomics, Inc · Filed Aug 27, 2018
Insider Transaction Report
Form 4
DP VIII Associates, L.P.
10% Owner
Transactions
- Conversion
Common Stock
2018-08-23+4,386→ 4,386 total - Conversion
Series C Preferred Stock
2018-08-23−40,268→ 0 total→ Common Stock (941 underlying) - Conversion
Series D Preferred Stock
2018-08-23−47,460→ 0 total→ Common Stock (1,109 underlying) - Conversion
Series D-1 Preferred Stock
2018-08-23−27,328→ 0 total→ Common Stock (638 underlying) - Conversion
Convertible Promissory Note
2018-08-23→ 0 totalExercise: $4.59→ Common Stock (2,505 underlying) - Conversion
Common Stock
2018-08-23$4.59/sh+2,505$11,498→ 6,891 total - Conversion
Series B Preferred Stock
2018-08-23−50,532→ 0 total→ Common Stock (1,180 underlying) - Conversion
Series B-1 Preferred Stock
2018-08-23−22,161→ 0 total→ Common Stock (518 underlying)
Footnotes (3)
- [F1]All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The Preferred Stock had no expiration date
- [F2]The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
- [F3]The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $11,048. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 75% of the IPO price per share of $6.125 per share.